Table 3.
Types of MAT medications among alcohol-dependent adults with severe mental illness in Connecticut public behavioral health system (n=896)
| MAT sample by SMI diagnosis | Full MAT Sample (n=896) | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Schizophrenia spectrum (n=249) | Bipolar disorder (n=278) | Major depression (n=369) | ||||||
|
| ||||||||
| N | % | N | % | N | % | N | % | |
|
|
||||||||
| Index treatment episode | ||||||||
| Naltrexone | 106 | 42.57 % | 123 | 44.24 % | 123 | 33.33 % | 352 | 39.29 % |
| Number of days, if any (Mean, SD) | 61.47 | (66.39) | 52.09 | (60.33) | 46.15 | (55.52) | 52.84 | (60.77) |
| Acamprosate | 121 | 48.59 % | 133 | 47.84 % | 216 | 58.54 % | 470 | 52.46 % |
| Number of days, if any (Mean, SD) | 47.69 | (54.36) | 50.03 | (61.54) | 38.05 | (37.74) | 43.92 | (50.05) |
| Disulfiram | 22 | 8.84 % | 22 | 7.91 % | 30 | 8.13 % | 74 | 8.26 % |
| Number of days, if any (Mean, SD) | 80.73 | (115.94) | 41.64 | (41.65) | 48.57 | (65.79) | 56.07 | (79.72) |
| Full 12-month follow-up (includes index and any subsequent episodes)* | ||||||||
| Naltrexone | 113 | 45.38 % | 136 | 48.92 % | 141 | 38.21 % | 390 | 43.53 % |
| Number of days, if any (Mean, SD) | 104.09 | (97.24) | 85.30 | (82.72) | 62.62 | (70.86) | 82.55 | (84.77) |
| Acamprosate | 129 | 51.81 % | 149 | 53.60 % | 225 | 60.98 % | 503 | 56.14 % |
| Number of days, if any (Mean, SD) | 71.29 | (76.50) | 77.62 | (76.00) | 63.22 | (62.91) | 69.55 | (70.71) |
| Disulfiram | 25 | 10.04 % | 26 | 9.35 % | 37 | 10.03 % | 88 | 9.82 % |
| Number of days, if any (Mean, SD) | 109.48 | (121.35) | 73.04 | (67.26) | 58.68 | (70.98) | 77.35 | (88.87) |
*
Total percentages exceed 100% because 85 individuals received more than one type of MAT over 12 months post-index treatment initiation.